






Disclosures	
Ocular Therapeulla O Galata O Hatian O Audel O Everance O Alcon O Tanus	O Trato O Kalo Nordit O Konti O Konti O Crasis O Krit O Crasis O Krit O Crasis D Trit


3














#### mportance of Early Diagnosis

- As keratoconus progresses, it becomes more challenging to manage
- Keratoconus can be easily overlooked in patients who are currently functioning well in spectacle lenses
- Imp tant to diagnose and educate patients before visual function is lost
- Cross-linking is an early intervention intended to halt or slow the progression of ker Even after the cross-linking procedure, keratoconus par and ongoing comeal and ocular health monitoring ents will still require












KERATOCONU	S: KNOWN CL	INICAL CORR	ELATIONS
	-0-		
Ocular Allergies	Eye Rubbing	Floppy Eyelids	Atopic Dermatitis
Asthma	Sleep Apnea	Family History	Connective Tissue Disorders such as Down or Harbonijendromes


Le	ook out for warning signs in medical history	
÷	Family history of keratoconus	T 000 11.
	Chronic eye rubbing and/or atopic eye diseases	all gally and
	Systemic associations - Down syndrome - Connective tissue disorders	
Le	ook out for patient symptoms	10
	Reduced visual quality or loss of vision	1000 Total 1000
	Giare, halo, ghosting, and/or monocular diplopia (especially at night)	
	Prequent changes in glasses prescriptions or contact lens refits	
La	ook out for refractive anomalies	and the second sec
	Distortion of mines on keratometry	
	Error messages on autorefractors	
	Unsatisfactory attempts at vision correction & progressive loss of UCVA & BCVA	10
	increasing autionatism	-































































	TABLE 3					
	Targeted		loted by ch			
	Gene	syloBand		cytoBand		rytaBand
	ABCA4	1,524	PKM	5413-1	00009	13452.3
	7AC5732	1982.1	ADGRV2	5424.3	COLAAJ	28484
	FORES	2,933	6GK	\$423.3	COLANZ	13484
	COLEA2	1934.3	TSFM	5481.1	17892	54424.3
	ANGPTC7	1036.22	CHPH1	5481.3	MAP2KT	15422.31
Known Keratoconus Genes	act to a	1036.22		6q13	AGBLE	15425.3
	LIBRADO	1036.22	/YN	6621	ABCCG	16g13.31
	G.44	16712	6.6	7p15.3	<b>CAT</b>	26422.3
	5461	1671.3	ABCBS	7221.3	ADAM753	
	c11	5482.5	1137	7621.11	CAS76	26423.3
	MATES .	5442.53	PRICE	7622.3	210.465	36424.2
	P1074	2925.3	P7K2	8424.3	NLRP2	17913.2
	A13	2453	13,8/3	9943.3	KR712	37621.2
	K14V	3q13	GSN	9433.2	KR713	17421.2
Genes	MAP3K2		COL541	9634.3	KR715	17821.2
	C01542	2432.2	(TG82	10p11.22	KP715	171212
	PATTAT	2454	2882	1091122	KR723	17621.2
~	COLAS	2436.3	\$7790	10972.3	60724	17621.2
	COLAN	2436.3		10934.33	WINTER	37623.32
	ACK8	3922.92	PA85	15p13	7014	38621.2
	84/2	3025.2	86572	15q12.3	505	19q13.32
	L8952	3036.2	COX242	13q13.11	2582	20µ11.21
	ACCX.	3q21.1	6873	12q13.13	00012	20911.23
	PROMS	4627	KERA	12021.33	SCHAIL	20913
	CIPRV2	4135.2	PXV	12074.23	COLGAI	21622.3










Two Types Of Gene BASED ON DISEASE CHARACTERIS	
Monogenic Disease	Polygenic Disease
One gene Multiple variants Answer: Presence (Yes/No) TGFBI Corneal Dystrophies	Multiple genes Thousands of variants Answer: Risk score Keratoconus







OCUL	AR DIAG	NOSTIC	ASSES	SMEN	r						
	0			2		€		l I	0		
	Family History	Red I	Flags In Y	bunger P	atients	Refra	active terns		neal Refra gery Decis		
	or CD	Concess inthe consu- top5504yor aything that	stallation in pages	640136	patrienter,	Uestable refactors patiente monara		C.	Randerice a Didrida		CO CO LABIE VI Victoria Marcala
For Early Diagnose & MANAREPEOPOE	dagnosis (B)	enintitik an	patients	. HEIMIR	٠	edgration		ettea	 	6,6534	
For Convel Croudinking IOSJ Decisions											













iton mindunenti Irland nishatad nishardi sundatga anafatin sunda a conglections anafan hwaund kel		
alinki bekim conjuticie apellaticie (1177		


Newer Treatments

Scleral contact lens
 Infacs conteal inplant
 Partial Comeal Transplant
 o besp Anterior Lenseler Kenteplasty (DALK)
 Comed CrossRiving
 """only option that can help slow or stop pragree
















## Presenting.....Corneal Crosslinking UV light and photoensilizer to strengthen chemical bonds in the came O stature deamlation reaction with ends chains of cologen O Approved in the US 2016 by FDA O taction et screet O Indicated to help slow progression of:

- Ceratoconus
   Ceratoconus
   PMD
   Terrien Marginal Degeneration
   Post- refractive surgery ectasia

55


**FDA-Approved Cross-Linking Procedure** 

56

Photrexa <sup>®</sup> Viscous (nbo and	flavin 5'-phosphate in 2	0% dextran ophthalm	ic solution)1
Photrexa® (riboflavin 5'-	hosphate ophthalmic s	olution)1	
are photoenhancers indi	ated for use with the		
KXL <sup>®</sup> ultraviolet light deli Procedures. <sup>2</sup>	very system in corneal	collagen cross-linking	ch in
	utactured		1

FDA-Approved Corneal Cross-Linking ions Progressive Keratoconus & Corneal Ectasia Following Refractive Surgery (Post-LASIK Ectasia LVSIK Eduaia Sachar Involvesi Epistelian merovial (Ej-off) 3 Jornin Indolman expolication & 530 min exposuse 355 mi UVA light, 3.0 mMtem<sup>3</sup> Intrasparative corneal inicineus minimum. 400 microns valad ri holdzwin and neactive oxygen species interact in cornea to form allikes: stiffen corneal site. Laboratory studies suggest 328.9% increase in biomechanical rigidity<sup>4</sup>

58






#### Cross-Linking not advised during pregnancy

Ulcerative keratilis can occur; most commo ocular adverse reaction was conneal opacity (haze) Other side effects may include punctate keratilis, corneal striae, dry eye, corneal epitelium defect, eye pain, light sensitivity; reduced visual acuity & blurred vision.







60














DA-approved cross-linking was		0000	<b>\$</b> 3.6		<b>\$</b> 32				3.8
associated with:		10.000							3.8
I ower total direct medical costs		2100							3.8
<ul> <li>Lower total direct medical costs (-\$8,677; \$30,994 vs. \$39,671) and more</li> </ul>									
QALYs (quality-adjusted life years, 1.88: 21.80 vs. 19.93).	1	0440		•25					
1.00, A1.00 00. 10.003.		\$1,40				10. 10.			** §
Reduction in lifetime costs of \$43,759	1 I	1440							18
(including loss of productivity), and lifetime		1100	-		1000			1441	2.8
reduction in out-of-pocket costs of \$4,248.		1.181	Ĩ	61.XL	Ĩ		10.04		**
US national savings of \$150 MM per year			а.	н.	а.		н.	а.	
with conservative prevalence estimates		~	-	8000		1000	- 14	NOL	
(1 in 2000), increasing to \$736 MM with	hard		100	1121	10.07	NO	182H	2161	
prevalence 1 in 375	1 lyonia 1 havin	la rienan	5.84	\$8.96	12,05	\$2.82	12,12	\$1.50	
prevalence i in 212.		in .	5485	10	50.52	9178	50.53	5.00	
	1.75		104	-	100	11.45	100	11.01	
		FIRST,	508	*	548	N	58	<b>K</b>	
	*11		2420	*	34.88		26.04	*	


















## What to Expect with Epi-On CXL

73

- Week I
   Source and phrase
   Source and phrase
   Source and phrase
   Source and a max to a source and a sourc

C Endotheted cell domoge
 0 - 445um Bitchess
 0 - Persident egithetid cellects: (pc) cfl)
 0 - Beschen legithetid cellects: (pc) cfl
 0 - Scoring
 0 - Endotsus kentifis
 0 - Fungi konsteine. HVX acasihamaeba
 0 - HVY v19V tgbi

**CXL** Complications

### 74

# Contraindications Comed Nickness -400um Nicr herpetic infection Concurrent Infection Severe concurrent scatting or opacification History of poor epithelial wound heating Severe occurs unface disease Autoimmune disorders


75



76



77





79